Hazel Staton has a BSc from The University of Sheffield in biochemistry and graduated in 2007. Upon graduation, Hazel joined Labcorp Biopharmaceutical CMC Services as a QC analyst in the molecular biology department and progressed to become a QC scientist focusing on the molecular biology support for molecules in the preclinical and clinical stages of development as well as wider CMC analytical strategies
Hazel is currently a Lead Scientist within the GMP R&D team within BioPharmaceutical CMC Solutions and provides scientific and regulatory leadership for a range of modalities including monoclonal antibodies, vaccines, and cell and gene therapy, focusing on the molecular biology support for molecules across CMC analytical strategies. Hazel liaises with both internal and external industry experts to maximize LabCorp's analytical capabilities and is part of an integrated team delivering innovative analytical solutions for client programs.
Area of expertise: Cell and Gene Therapy, Quality Control
Publications:
- Good Laboratory Practice PreClinical Safety Studies for GSK2696273, Human Gene Therapy Clinical Development Vol. 28, No. 1, March 2017
- Cell & Gene Therapy Answers: Addressing Complex Analytical Needs with ddPCR/qPCR, October 2021